Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03095482 · ClinicalTrials.gov registry record · NA
tDCS-Augmented Exposure Therapy for Pathological Fear
A NA study, sponsored by University of Texas at Austin.
- Completed
- Registry status
- NA
- Development phase
- 49
- Enrollment target
NCT03095482 is a NA study that has completed, run by University of Texas at Austin. The registered enrollment target is 49 participants.
The verdict
NCT03095482, a NA study, has completed, sponsored by University of Texas at Austin.
- COMPLETED
- Registry status
- NA
- Development phase
- 49 participants
- Enrollment target
Study Summary
This double-blind randomized controlled clinical trial aims to test whether transcranial direct current stimulation (tDCS) can be used to modulate fear extinction learning during exposure therapy for pathological fear, including fear of spiders, snakes, or germs / contamination. Participation takes place over three laboratory visits, including (1) a pre-treatment visit, (2) a treatment and post-treatment visit, and (3) a 1 month follow-up visit. During treatment, participants will receive either 20 minutes of active or sham tDCS, followed by 30 minutes of in vivo exposure therapy.
Interventions
- DEVICE Transcranial Direct Current Stimulation (tDCS)
- BEHAVIORAL In vivo exposure therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2017-01-01 |
| Est. Completion | 2018-09-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03095482
The ClinicalTrials.gov registry entry for NCT03095482 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas at Austin, which has 257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Transcranial Direct Current Stimulation (tDCS) is the first listed.
NCT03095482 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03095482 about?
NCT03095482 is a clinical study titled "tDCS-Augmented Exposure Therapy for Pathological Fear". This double-blind randomized controlled clinical trial aims to test whether transcranial direct current stimulation (tDCS) can be used to modulate fear extinction learning during exposure therapy for pathological fear, including fear of spiders, snakes, or germs / contamination. Participation takes ...
What is the current status of trial NCT03095482?
This trial is currently completed. It is a NA study. The enrollment target is 49 participants. The study started on 2017-01-01. Estimated completion is 2018-09-06.
What interventions are being tested in trial NCT03095482?
The interventions under investigation include: Transcranial Direct Current Stimulation (tDCS) (DEVICE), In vivo exposure therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT03095482?
This trial is sponsored by University of Texas at Austin, which has 257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.